MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2019 International Congress

    The Effects of Apomorphine infusion on Head ptosis, a case report

    O. Skogar (Stockholm, Sweden)

    Objective: Sustained Effects of Apomorphine infusion on Head Ptosis, a case report Background: IntroductionHead ptosis (Hp) results from weakness of the neck extensor, or increased…
  • 2019 International Congress

    Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017

    L. Tönges, D. Bartig, C. Krogias, D. Richter (Bochum, Germany)

    Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…
  • 2019 International Congress

    Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine

    RWK. Borgemeester, GFH. Diercks, T. van Laar (Groningen, Netherlands)

    Objective: To evaluate the efficacy of 4 treatment modalities on apomorphine-induced subcutaneous nodules as compared to no treatment. Background: Subcutaneous nodules are the most common adverse events…
  • 2019 International Congress

    Apomorphine induced hemolytic anemia: A case report and literature review

    F. Hajiakhoundi, M. Motamed, M. Rohani, G. Shahidi (Tehran, Islamic Republic of Iran)

    Objective: To present a case of apomorphine induced hemolytic anemia Background: Drug induced immune hemolytic anemia (DIIHA) is a potentially lethal adverse reaction; It has…
  • 2019 International Congress

    Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes

    F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

    Objective: Exposure-response models were developed to characterize the relationship between apomorphine exposure and (1) efficacy using Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease…
  • 2019 International Congress

    Population Exposure-Response Modeling of the Effects of Apomorphine Sublingual Film on QTc in Patients With Parkinson’s Disease and “OFF” Episodes

    F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

    Objective: To characterize the relationship between plasma apomorphine concentrations and QTc (QT interval corrected for heart rate) in patients with Parkinson’s disease (PD) and “OFF”…
  • 2019 International Congress

    The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials

    M. Azharuddin, M. Adil, P. Ghosh, M. Sharma (New Delhi, India)

    Objective: The objective of this study to evaluate the efficacy and safety of subcutaneous apomorphine for patients with Parkinson’s disease (PD). Background: Subcutaneous apomorphine has…
  • 2019 International Congress

    The prevalence of ICBs in patients treated with apomorphine infusion: a retrospective analysis

    P. Barbosa, A. Lees, A. Djamshidian, T. Warner (Innsbruck, Austria)

    Objective: To assess the prevalence of impulsive compulsive behaviours (ICBs) in Parkinson’s disease who donated their brains and used apomorphine infusion in life. Background: Impulsive…
  • 2019 International Congress

    Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study

    J. Hui, S. Fox, W. Neeson, P. Bhargava, E. Pappert, D. Blum, B. Navia (Los Angeles, CA, USA)

    Objective: To compare time to onset and magnitude of motor improvement following administration of apomorphine sublingual film (APL-130277; APL) vs levodopa in patients with Parkinson’s…
  • 2019 International Congress

    The Power of Normal Saline in Reducing Skin Nodules in Apomorphine

    F. Leen, A. Evans, T. Canento, M. Ghaly, C. Wools, B. Cruse, M. Beckley (Melbourne, Australia)

    Objective: This is a poster presentation Background: Continuous apomorphine therapy is a pump delivered infusion via subcutaneous injection for management of advanced therapy in Parkinson's…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley